CA3140989A1 - Compositions comprenant des acides gras cetyles et leur utilisation dans le traitement de l'arthrite et des etats inflammatoires articulaires - Google Patents

Compositions comprenant des acides gras cetyles et leur utilisation dans le traitement de l'arthrite et des etats inflammatoires articulaires Download PDF

Info

Publication number
CA3140989A1
CA3140989A1 CA3140989A CA3140989A CA3140989A1 CA 3140989 A1 CA3140989 A1 CA 3140989A1 CA 3140989 A CA3140989 A CA 3140989A CA 3140989 A CA3140989 A CA 3140989A CA 3140989 A1 CA3140989 A1 CA 3140989A1
Authority
CA
Canada
Prior art keywords
cetylated
composition
acid
mixture
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140989A
Other languages
English (en)
Inventor
Andrea Lacorte
Germano Tarantino
Elisa BRILLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmanutra SpA
Alesco SRL
Original Assignee
Pharmanutra SpA
Alesco SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmanutra SpA, Alesco SRL filed Critical Pharmanutra SpA
Publication of CA3140989A1 publication Critical patent/CA3140989A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

La présente invention concerne une composition comprenant un mélange comprenant, ou en variante, constitué d'au moins un acide gras cétylé ou d'un mélange d'acides gras cétylés et d'un antioxydant en pourcentages en poids réduits, ladite composition étant destinée à être utilisée dans des procédés de traitement de l'arthrite et de la douleur musculo-squelettique et articulaire inflammatoire. En outre, la présente invention concerne une composition comprenant un mélange comprenant, ou en variante, constitué d'au moins un acide gras cétylé ou d'un mélange d'acides gras cétylés et, éventuellement, d'un antioxydant, ladite composition étant destinée à être utilisée dans des procédés de traitement pour protéger la muqueuse gastrique et pour réguler les taux de glycémie. Enfin, la présente invention concerne un procédé de préparation dudit au moins un acide gras cétylé ou d'un mélange d'acides gras cétylés et de préparation de compositions comprenant lesdits acides gras cétylés et ledit antioxydant.
CA3140989A 2019-05-27 2020-05-27 Compositions comprenant des acides gras cetyles et leur utilisation dans le traitement de l'arthrite et des etats inflammatoires articulaires Pending CA3140989A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102019000007326 2019-05-27
IT102019000007326A IT201900007326A1 (it) 2019-05-27 2019-05-27 Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
PCT/IB2020/055028 WO2020240438A1 (fr) 2019-05-27 2020-05-27 Compositions comprenant des acides gras cétylés et leur utilisation dans le traitement de l'arthrite et des états inflammatoires articulaires

Publications (1)

Publication Number Publication Date
CA3140989A1 true CA3140989A1 (fr) 2020-12-03

Family

ID=67957311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140989A Pending CA3140989A1 (fr) 2019-05-27 2020-05-27 Compositions comprenant des acides gras cetyles et leur utilisation dans le traitement de l'arthrite et des etats inflammatoires articulaires

Country Status (13)

Country Link
US (1) US12383525B2 (fr)
EP (1) EP3976184A1 (fr)
JP (1) JP7689083B2 (fr)
CN (1) CN114126581A (fr)
BR (1) BR112021022965A2 (fr)
CA (1) CA3140989A1 (fr)
IL (1) IL288269A (fr)
IT (1) IT201900007326A1 (fr)
MA (1) MA56040A (fr)
MX (1) MX2021014371A (fr)
SG (1) SG11202112774XA (fr)
UA (1) UA129569C2 (fr)
WO (1) WO2020240438A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700089258A1 (it) 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
IT201900007326A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
IT201900007329A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati per uso nel trattamento della mucosa gastrica, diabete e alti livelli di glicemia
IT201900007311A1 (it) 2019-05-27 2020-11-27 Alesco Srl Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati
IT202100030170A1 (it) * 2021-11-29 2023-05-29 Pharmanutra S P A Cerotto transdermico, e uso di detto cerotto in un metodo di trattamento di un disturbo, o disordine, o patologia, di un tendine
IT202300004227A1 (it) * 2023-03-07 2024-09-07 Pharmanutra S P A Composizioni comprendenti acidi grassi cetilati e vitamina d, e loro usi relativi

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049824A (en) 1976-05-03 1977-09-20 Harry Weldon Diehl Cetyl myristoleate
US4393133A (en) 1980-06-12 1983-07-12 The Wistar Institute Of Anatomy And Biology Human hepatoma derived cell line, process for preparation thereof, and uses therefor
JPH0244806B2 (ja) * 1981-09-07 1990-10-05 Sunstar Kk Bitaminaoanteinihaigoshitanyukakeihifugaiyozaisoseibutsu
JP3860849B2 (ja) 1994-04-28 2006-12-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗動脈硬化治療剤
EP0679394B1 (fr) 1994-04-28 1998-01-14 Eisai Co., Ltd. Dérivé du Menatetrenome comme agent antiartériosclérotique
US6461622B2 (en) 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
CA2222278C (fr) 1995-06-06 2008-05-13 Campbell Soup Company Complements alimentaires a base de mineraux pour repas dietetique
US5707670A (en) 1996-08-29 1998-01-13 The Procter & Gamble Company Use of bilayer forming emulsifiers in nutritional compositions comprising divalent mineral salts to minimize off-tastes and interactions with other dietary components
CU22723A1 (es) 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
NZ332959A (en) 1998-11-23 2001-09-28 Yasho Ind Pvt Ltd Preparation of cetyl myristate and cetyl palmitate
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
US6361800B1 (en) 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
AU2001290367B2 (en) 2001-08-31 2008-06-19 Lypanosys Pte Limited Synthesis of ester linked long chain alkyl moieties
JP2003342159A (ja) 2002-03-18 2003-12-03 Nikko Chemical Co Ltd 皮膚老化防止化粧料
US7772279B2 (en) 2002-03-21 2010-08-10 Botanoceuticals, Inc. Use of vegetable butter-based cetyl myristoleate for treating osteoarthritis and other musculoskeletal disease conditions and injuries
GB0220182D0 (en) 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
AU2004224332A1 (en) 2003-03-20 2004-10-07 Imagenetix, Inc. Esterified fatty acid composition
AU2004287440A1 (en) 2003-10-28 2005-05-19 Emory University Dialysates and methods and systems related thereto
US20050100636A1 (en) 2003-11-10 2005-05-12 Megan Botteri [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity]
US7585527B2 (en) 2005-09-19 2009-09-08 Bala Venkataraman Composition and method for treating iron deficiency anemia
EP1790356A1 (fr) 2005-11-24 2007-05-30 Vifor (International) Ag Préparation contenant des complexes de fer(III) et des composés rédoxs
ES2634142T3 (es) 2005-12-23 2017-09-26 Ajay Gupta Composición de nutrición parenteral que contiene hierro
EP1978808B1 (fr) 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Citrate de fer pour inverser, prévenir, retarder ou stabiliser la calcification des tissus mous
ITMI20080145A1 (it) 2008-01-30 2009-07-31 Pharmanutra S R L Uso di acido eicosapentanoico e/o docosaesanoico in donne con endometriosi
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
JPWO2010073642A1 (ja) 2008-12-25 2012-06-07 有限会社 アイ・ビー・イー 生物活性剤、医薬、化粧品、鮮度保持剤、および植物および動物の発育促進剤
CN102348482B (zh) 2009-01-12 2014-05-14 科学与工业研究委员会 用于制备顺式-9-十四碳烯酸十六烷基酯和顺式-10-十四碳烯酸十六烷基酯的方法
KR20100111040A (ko) 2009-04-06 2010-10-14 정시남 지방산 계열 화합물을 유효성분으로 함유하는 위장 질환 예방 또는 치료용 조성물
US8404745B2 (en) * 2011-03-16 2013-03-26 Raj R. Barathur Transdermal delivery of medicinal cetylated fatty esters using phonophoresis or iontophoresis
CN103687495A (zh) 2011-05-20 2014-03-26 弗里斯兰品牌有限公司 包含维生素k2的组合物
US20140121156A1 (en) 2011-06-13 2014-05-01 Entia Biosciences, Inc. Nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
ITMI20121350A1 (it) 2012-07-31 2014-02-01 Alesco Srl Composizione solido a base di ferro per uso nelle condizioni di deficienza di ferro.
WO2014160279A1 (fr) 2013-03-13 2014-10-02 Viroxis Corporation Formulations de crème stabilisées comprenant de l'essence de santal
US20140322314A1 (en) 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
EP2886129A1 (fr) 2013-12-20 2015-06-24 VitaK B.V. Prévention et action contraire de risque de thrombose induite par le régime alimentaire
EP3258924A2 (fr) 2015-02-20 2017-12-27 VitaK B.V. Statut en vitamine k et fonction capillaire
ITUB20153130A1 (it) 2015-08-14 2017-02-14 Pharmanutra S P A Acidi grassi cetilati, impianto per la loro preparazione e relativo uso
US9579357B1 (en) 2015-08-31 2017-02-28 Anc Products, Llc Therapeutic compositions
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
US20170202802A1 (en) 2016-01-20 2017-07-20 Exeltis Usa, Inc. Compositions, kits and methods for nutrition supplementation
GB2552952B (en) * 2016-08-12 2020-03-04 Norbrook Lab Ltd Moxidectin topical liquid formulations
US11344575B2 (en) 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
CN106343566A (zh) 2016-08-30 2017-01-25 李洋 一种慢性肾病患者用的特殊医用食品配方及其生产工艺
EP3632406B1 (fr) 2017-05-30 2024-03-13 The Nisshin OilliO Group, Ltd. Hydratant huileux et composition topique pour la peau le contenant
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
IT201700089258A1 (it) 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
IT201900007326A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
IT201900007329A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati per uso nel trattamento della mucosa gastrica, diabete e alti livelli di glicemia
IT201900007311A1 (it) 2019-05-27 2020-11-27 Alesco Srl Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati

Also Published As

Publication number Publication date
MX2021014371A (es) 2022-02-21
MA56040A (fr) 2022-04-06
WO2020240438A1 (fr) 2020-12-03
SG11202112774XA (en) 2021-12-30
US12383525B2 (en) 2025-08-12
IT201900007326A1 (it) 2020-11-27
CN114126581A (zh) 2022-03-01
US20220211655A1 (en) 2022-07-07
JP7689083B2 (ja) 2025-06-05
BR112021022965A2 (pt) 2022-01-04
EP3976184A1 (fr) 2022-04-06
JP2022544894A (ja) 2022-10-24
IL288269A (en) 2022-01-01
UA129569C2 (uk) 2025-06-04

Similar Documents

Publication Publication Date Title
US12383525B2 (en) Compositions comprising cetylated fatty acids and use thereof for the treatment of arthritis and joint inflammatory conditions
US20250270472A1 (en) Method for preparing a composition comprising cetylated fatty acids
EP3976023B1 (fr) Compositions comprenant des acides gras cétylés, destinées à être utilisées dans le traitement de la muqueuse gastrique
CN100348184C (zh) 含有高度不饱和脂肪酸、其盐或其酯的外用组合物
CN1796388B (zh) 芝麻素/异芝麻素组合物
JP4002654B2 (ja) 血中脂質改善剤、サイクリックａｍｐホスホジエステラーゼ阻害剤、及び肥満の予防・解消剤、並びに飲食品及び皮膚外用剤
AU666748B2 (en) Fatty acid treatment
JPH06199688A (ja) 面皰治療剤組成物
HK40072479A (en) Compositions comprising cetylated fatty acids for use in the treatment of gastric mucosa
HK40072479B (en) Compositions comprising cetylated fatty acids for use in the treatment of gastric mucosa
HK40072481A (en) Method for preparing a composition comprising cetylated fatty acids
HK40072481B (en) Method for preparing a composition comprising cetylated fatty acids
EA045244B1 (ru) Способ приготовления композиции, содержащей цетилированные жирные кислоты
EA049574B1 (ru) Композиции, содержащие цетилированные жирные кислоты, и их применение в лечении артрита и воспалительных состояний суставов
US20030086981A1 (en) Glycerin fatty acid ester for palliate a symptom of premenstrual syndrome, a palliative of premenstrual syndrome, oil or fat composition for palliate a symptom of premenstrual syndrome, and food and drink for palliate a symptom of premenstrual syndrome
Viola et al. Olive oil as a skin protector
JP5256456B2 (ja) 脂質代謝改善剤
Viola et al. 17. Olive oil as a skin protector

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240924

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250627

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250627

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250718

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250718

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250721

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P124 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT AFTER ALLOWANCE (AAA) RECEIVED

Effective date: 20260217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT AFTER ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260218

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260218

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260423

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260520

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260710

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260710

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728